![Mark Lackner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Lackner
Geen lopende functies
Vermogen: 779 260 $ op 31-08-2026
Profiel
Mark Lackner worked at Genentech, Inc. from 2012 to 2018, serving as Director from 2015 to 2018.
From 2018 to 2022, worked at IDEAYA Biosciences, Inc. as SVP, Head-Biology & Translational Sciences.
From 2022 to 2025, worked at Zentalis Pharmaceuticals, Inc. as Chief Scientific Officer from 2023 to 2025.
Education includes a doctorate from Stanford University conferred in 1997, an undergraduate degree from the University of Illinois At Urbana–Champaign in 1990, and a graduate degree from the same institution in 1991.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 20-04-2026 | 207.250 ( 0,22% ) | 779 260 $ | 31-08-2026 |
Eerdere bekende functies van Mark Lackner
| Bedrijven | Functie | Einde |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2025 |
| IDEAYA BIOSCIENCES, INC. | Corporate Officer/Principal | 01-10-2022 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Directeur/Bestuurslid | 01-05-2018 |
Opleiding van Mark Lackner
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
96
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IDEAYA Biosciences, Inc.
 IDEAYA Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as oncology-focused precision medicine company which develops and sells cancer therapeutics | Health Technology |
University of Illinois At Urbana–Champaign
 University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zentalis Pharmaceuticals, Inc.
 Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
